Digoxin for atrial fibrillation and atrial flutter: A systematic review with meta-analysis and trial sequential analysis of randomised clinical trials

Sethi, Naqash J; Nielsen, Emil Eik; Safi, Sanam; Feinberg, Joshua; Gluud, Christian; Jakobsen, Janus Christian

doi:10.1371/journal.pone.0193924

Cited by 45 publications

(45 citation statements)

References 103 publications

(78 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The incidence and prevalence of atrial fibrillation are increasing each year, and this condition is one of the most common clinical arrhythmias[ 1 , 2 ]. Atrial fibrillation leads to stroke, thromboembolic events, heart failure, myocardial infarction, and cognitive decline, as well as an increased risk of chronic kidney disease and other diseases[ 3 ]. The identification of useful serological markers can provide guidance for the primary prevention of atrial fibrillation and for monitoring and evaluating treatment efficacy and prognosis[ 4 ].…”

Section: Introductionmentioning

confidence: 99%

Significance of serum fibroblast growth factor-23 and miR-208b in pathogenesis of atrial fibrillation and their relationship with prognosis

Chen¹,

Zhong²,

Tu³

et al. 2020

WJCC

View full text Add to dashboard Cite

BACKGROUND The incidence and prevalence of atrial fibrillation are increasing each year, and this condition is one of the most common clinical arrhythmias. AIM To investigate the levels and significance of serum fibroblast growth factor 23 (FGF-23) and miR-208b in patients with atrial fibrillation and their relationship with prognosis. METHODS From May 2018 to October 2019, 240 patients with atrial fibrillation were selected as an observation group, including 134 with paroxysmal atrial fibrillation and 106 with persistent atrial fibrillation; 150 patients with healthy sinus rhythm were selected as a control group. The serum levels of FGF-23 and miR-208b in the two groups were measured. In the observation group, cardiac parameters were determined by echocardiography. RESULTS The serum levels of FGF-23 and miR-208b in the observation group were 210.20 ± 89.60 ng/mL and 5.30 ± 1.22 ng/mL, which were significantly higher than the corresponding values in the control group ( P < 0.05). In the observation group, the serum levels of FGF-23 and miR-208b in patients with persistent atrial fibrillation were 234.22 ± 70.05 ng/mL and 5.83 ± 1.00 ng/mL, which were significantly higher than the corresponding values in patients with paroxysmal atrial fibrillation ( P < 0.05). The left atrial dimension (LAD) of patients with persistent atrial fibrillation was 38.81 ± 5.11 mm, which was significantly higher than that of patients with paroxysmal atrial fibrillation ( P > 0.05). The serum levels of FGF-23 and miR-208b were positively correlated with the LAD ( r = 0.411 and 0.382, P < 0.05). In the observation group, the serum levels of FGF-23 and miR-208b in patients with a major cardiovascular event (MACE) were 243.30 ± 72.29 ng/mL and 6.12 ± 1.12 ng/mL, which were significantly higher than the corresponding values in patients without a MACE ( P < 0.05). CONCLUSION The serum levels of FGF-23 and miR-208b are increased in patients with atrial fibrillation and are related to the type of disease, cardiac parameters, and prognosis.

show abstract

Section: Introductionmentioning

confidence: 99%

Significance of serum fibroblast growth factor-23 and miR-208b in pathogenesis of atrial fibrillation and their relationship with prognosis

Chen¹,

Zhong²,

Tu³

et al. 2020

WJCC

View full text Add to dashboard Cite

show abstract

“…85 86 The method has previously been applied by our group in systematic reviews with meta-analysis on a wide range of healthcare topics. [87][88][89][90][91][92][93][94] A PRISMA-P checklist file is attached (online supplementary additional file 1).…”

Section: Methods and Analysismentioning

confidence: 99%

Effects of adding adjunctive hyperbaric oxygen therapy to standard wound care for diabetic foot ulcers: a protocol for a systematic review with meta-analysis and trial sequential analysis

et al. 2020

View full text Add to dashboard Cite

IntroductionDiabetic foot ulcer represents a major health problem globally. Preliminary studies have indicated that systemic treatment of diabetic foot ulcer patients with hyperbaric oxygen therapy have beneficial effects on wound healing, risk of amputation, glycaemic control, atherosclerosis, inflammatory markers and other clinical and laboratory parameters. This protocol for a systematic review aims at identifying the beneficial and harmful effects of adding hyperbaric oxygen therapy to standard wound care for diabetic foot ulcers.Methods and analysisThis protocol was performed following the recommendations of the Cochrane Collaboration and the eight-step assessment procedure suggested by Jakobsen and colleagues. We plan to include all relevant randomised clinical trials assessing the effects of hyperbaric oxygen therapy in the treatment of diabetic foot ulcer versus any control group with any intervention defined as standard wound care or similar, together with sham interventions. Our primary outcome will be: all-cause mortality, serious adverse events and quality of life. Our secondary outcomes will be: healing of index wound, major amputation and wound infection. Any eligible trial will be assessed and classified as either high risk of bias or low risk of bias, and our conclusions will be based on trials with low risk of bias. The analyses of the extracted data will be performed using Review Manager 5 and Trial Sequential Analysis. For both our primary and secondary outcomes, we will create a ‘Summary of Findings’ table and use GRADE (Grading of Recommendations Assessment, Development and Evaluation) assessment to assess the quality of the evidence.Ethics and disseminationWe use publicly accessible documents as evidence, there is no participant involvement at an individual level and an institutional ethics approval is not required. The results of the review will be sought published in a peer-reviewed journals, also in the event of insignificant results or null results, and thereby it will be disseminated to clinicians and public available.PROSPERO registration numberCRD42019139256.

show abstract

“…In AF, it has no role in rhythm control [111], and it remains a choice for rate control, on top of non-DHB-CCB or beta-blockers [112]. It is considered a positive inotropic agent, generally used in AF patients with heart failure and, due to its parasympathetic-mimetic property, a negative chronotropic and dromotropic drug [113]. During its administration, toxic levels have to be avoided and it is extremely important to check electrolyte imbalances (e.g.…”

Section: Drugs With No Proven Efficacy For Conversion Of Atrial Fibrimentioning

confidence: 99%

Cardioversion of recent-onset atrial fibrillation: current evidence, practical considerations, and controversies in a complex clinical scenario

Boriani¹,

Bonini²,

Albini³

et al. 2020

Kardiol Pol

View full text Add to dashboard Cite

show abstract

Digoxin for atrial fibrillation and atrial flutter: A systematic review with meta-analysis and trial sequential analysis of randomised clinical trials

Cited by 45 publications

References 103 publications

Significance of serum fibroblast growth factor-23 and miR-208b in pathogenesis of atrial fibrillation and their relationship with prognosis

Significance of serum fibroblast growth factor-23 and miR-208b in pathogenesis of atrial fibrillation and their relationship with prognosis

Effects of adding adjunctive hyperbaric oxygen therapy to standard wound care for diabetic foot ulcers: a protocol for a systematic review with meta-analysis and trial sequential analysis

Cardioversion of recent-onset atrial fibrillation: current evidence, practical considerations, and controversies in a complex clinical scenario

Contact Info

Product

Resources

About